LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Stock Could Sit Below Fair Value Despite Strong Returns
AstraZeneca stock has pulled back sharply in recent weeks even though a 56.7% gain over the past five years still leaves long term holders comfortably ahead, and the latest valuation checks suggest the current share price may sit well below an intrinsic value estimate. With both the Discounted Cash Flow (DCF) intrinsic value and market multiples pointing to AstraZeneca screening as undervalued, investors now have to weigh that against recent news driven volatility.
AstraZeneca has returned...